Log In

 

Company Name : Laurus Labs Ltd.

Tuesday, February 14, 2017 12:36AM IST (7:06PM GMT)

(BW)(LAURUS-LABS-LTD.)

Laurus Labs Demonstrates Strong Q3 Growth in the First Quarterly Results After Successful IPO


Hyderabad, India

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India announces its 9M & Q3 FY17 results.

 

9M FY17 results:

 
  • Total Revenue grew by 9.7% to Rs.14,459 mn from Rs.13,179 mn
  • EBITDA increased by 23.1% to Rs.3,199 mn versus Rs.2,598 mn
  • PAT higher by 40.5% to Rs.1,277 mn from Rs.909 mn
  • EPS (Diluted) for the period stood at Rs.12.9 per share (not annualised)

Q3 FY17 results:

 
  • Total Revenue grew by 12.3% to Rs.5,054 mn from Rs.4,501 mn
  • EBITDA increased by 9.4% to Rs.1,115 mn versus Rs.1,019 mn
  • PAT higher by 17.5% to Rs.472 mn from Rs.402 mn
  • EPS (Diluted) for the period stood at Rs.4.7 per share (not annualised)

Business Highlights – 9M FY17:

 
  • Prepayment of long term loans of Rs.2,263 million from IPO proceeds, Rs.585 million spent on general corporate purposes after meeting IPO expenses of Rs.150 million.
  • Capex investments in first nine months Rs.2,584 million.
  • R & D opex investments Rs.773 million and 5.3% as percentage of sales during Apr – Dec, 2016
  • In partnership with Laurus, Natco has launched Velpatasivir (Hep-C) product in Nepal and is geared up for launch in India upon approval.
  • As on Dec 2016, the Company has filed 202 patent applications and 37 patents granted.
  • Expansion of R & D centre at Hyderabad completed.
  • As on date filed 2 ANDAs and in addition completed 4 product validations.
  • Capacity expansion of 5 billion tablets is expected to complete by end Mar 17.
  • US FDA and WHO inspection scheduled during March 2017 for Unit 2.
  • FDF opex investments are Rs.821 million which includes Rs.253 million relating to the R& D during Apr – Dec, 2016
  • Unit 5 (dedicated manufacturing facility for Aspen) is inaugurated and is operational in Nov ‘16
  • Laurus signed manufacturing and supply agreement for Oncology NCE for clinical phase and commercial supplies
  • Dr. Satyanarayana Chava nominated as one of the members of US pharmacopeia Board of Trustees (BoT)
  • Laurus Labs received Pharmaexcil patent Silver Award for the contribution in the category of Bulk Drugs /APIs to India’s Pharmaceutical Exports during the year 2015-16

For more information about us, please visit http://www.lauruslabs.com.

 

 

 

 


Click here for Media Contact Details
CONTACTS : Laurus Labs Ltd.Pavan Kumar N, +91 40 3980 4380mediarelations@lauruslabs.com

More News from Laurus Labs Ltd.

13/11/2017 10:10AM

लॉरस लैब्‍स ने सुदृढ़ प्रदर्शन किया, वित्‍त वर्ष 2018 की पहली छमाही में कर पश्‍चात लाभ 19 प्रतिशत बढ़ा

लॉरस लैब्‍स लिमिटेड (लॉरस बीएसई :54022, एनएसई:लॉरसलैब्‍स, आइएसआइएल: आइएनई 947क्‍यू01010), भारत में एक प्रमुख अनुसंधान एवं विकास अभिप्रेरित फार्मास्‍युटिकल कंपनी, ने वित्‍त वर्ष 2018 की ...

10/11/2017 8:25PM

Laurus Labs Records Healthy Performance, PAT Grows at 19% in H1 FY18

Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company in India announces its Q2 & H1 FY18 results.   Q2 FY18 Laurus ...

19/05/2017 8:10PM

लॉरस लैब्स का कर के बाद लाभ (पीएटी) 40% बढ़ा; बोर्ड ने 15% के लाभांश की सिफारिश की

अनुसंधान और विकास आधारित भारत की अग्रणी फार्मास्यूटिकल कंपनी लॉरस लैब्स लिमिटेड (लॉरस) ने चौथी तिमाही और वित्त वर्ष 17 के अपने परिणामों की घोषणा की है।   विव17 लॉरस ने रिपोर्ट ...

Similar News

20/11/2017 9:30AM

New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases

AstraZeneca presented new data from a subgroup analysis of the Phase III FLAURA trial, which explored osimertinib as 1st-line therapy in patients with locally advanced or metastatic epidermal growth factor receptor ...

No Image

20/11/2017 9:15AM

New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer

AstraZeneca announced that the New England Journal of Medicine has published the positive results from the Phase III FLAURA trial which provide data for Tagrisso’s (osimertinib) use in the 1st-line treatment of ...